CSI Market
Sign In | Register

Altamira Therapeutics Ltd (CYTO) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CYTO Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Altamira Therapeutics Ltd balances growth, leverage, and shareholder equity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2025)
(Dec 31 2024) (Jun 30 2024) (Dec 31 2023) 0
Assets
Cash And Cash Equivalents0.00
Cash & Short-term Investments0.00
Inventories0.12
Other Current Assets0.00
Total Current Assets0.25
Equipment/Property/Plant Net0.10
Intangible Assets5.83
Other Assets, Noncurrent2.93
Total Assets8.98
Liabilities
Accounts Payable0.76
Current Portion Of Longterm Borrowings0.43
Other Liabilities, Current0.00
Total Current Liabilities2.91
Total Long-term Debt0.00
Other liabilities, Noncurrent2.66
Total Liabilities3.85
Stockholders' Equity
Common Stockholder's Equity5.13
Total Stockholder's Equity5.13
Liabilities & Stockholder's Equity8.98
4 historic quarters locked

Sign in to unlock the full Altamira Therapeutics Ltd balance sheet history.

Sign In Create Free Account

About Altamira Therapeutics Ltd Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001213900-25-037199

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.